We are always happy to read reports showing the growing interest of the research for high content screening. For those interested, you can find in this article to appear, an expert opinion on High Content Screening in the drug-discovery processes. The team of Fraietta & al(1) rated the number of semantic researches on the HCS on Pubmed. They detail the therapeutic areas covered by the HCS (neurological diseases, cardiovascular diseases, infectious diseases, oncology …), its role in the drug discovery process, but also all its future potential developments. Among these, one finds, in addition of the use of primary cells culture:

– The use of iPSCs[i],

– The adjustment of the technique for 3D cell cultures, tissues, organoids and even whole organisms (unicellular organisms like Saccharomyces cerevisiae, or multicellular organisms like the zebrafish),

– The development of engineered cell lines with genome editing techniques (to introduce a mutated driver oncogene, or to silence a tumor suppressor gene) including homologous recombination, approaches based on ZNF[ii], TALENs[iii] or CRISPRs[iv]/Cas9.

In the end, such an article confirms our choice of HCS as Core Development technology.

Opportunities for HCS

 

  1. Fraietta I, Gasparri F. The development of high-content screening (HCS) technology and its importance to drug discovery. Expert Opin Drug Discov. mai 2016;11(5):501-514.

 

[i] iPSCs = induced pluripotent stem cells

[ii]  ZNF = zinc-finger nucleases

[iii] TALENs = transcription activator like effector nucleases

[iv] CRISPRs = Clustered regularly interspaced short palindromic repeats